Clinical Trials Logo

Acute Coronary Syndrome clinical trials

View clinical trials related to Acute Coronary Syndrome.

Filter by:

NCT ID: NCT02520921 Active, not recruiting - Obesity Clinical Trials

Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

ANDAMAN
Start date: June 13, 2016
Phase: Phase 4
Study type: Interventional

To compare treatment with Aspirin Protect® twice a day (100 mg in the morning and 100 mg in the evening) versus Aspirin Protect® 100 mg once per day on a composite end-point of ischemic events in diabetic patients, or in patients with a known risk factor for non-optimal aspirin response (obesity, abdominal obesity or coronary event occurring with long-term aspirin),with acute coronary syndrome. It is expected that aspirin taken twice a day will reduce the occurrence of new ischemic event after acute coronary syndrome in diabetic patients or in patients with a known risk factor.

NCT ID: NCT02508714 Active, not recruiting - Clinical trials for Coronary Artery Disease

Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents

BIONYX
Start date: October 7, 2016
Phase: N/A
Study type: Interventional

The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity. However, the first generation of these devices had no positive impact on the mortality after PCI (compared to bare metal stents), which was greatly attributed to a somewhat increased incidence of late and very late stent thrombosis. Concerns about the role of durable polymers as a potential trigger of inflammation and finally adverse events also led to the development of DES with bioresorbable coatings, which leave after degradation of the coating only a bare metal stent in the vessel wall that does not induce an inflammatory response. While such bioresorbable polymer DES are increasingly used in clinical practice, data from head-to-head comparisons between bioresorbable polymer DES with a contemporary highly flexible new generation permanent polymer coated DES.

NCT ID: NCT02500290 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet

Start date: November 2014
Phase:
Study type: Observational

This study aims to describe antiplatelet therapy in ACS in Andalusia and make an assessment of efficacy and safety of hospital use Prasugrel / ticagrelor vs. Clopidogrel and Prasugrel switching to / ticagrelor patients pretreated with clopidogrel.

NCT ID: NCT02415452 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Researches of Retinal Artery Lesions and Acute Coronary Syndrome

REACS
Start date: July 2006
Phase: N/A
Study type: Observational

This study is to investigate the relationship between staging of retinal artery lesions and the prognosis of acute coronary syndrome (ACS) in a Chinese population. All the patients were divided into four groups according retinal artery lesions.The endpoints were main adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, myocardial infarction (MI), and stroke after 3 to 6 years of follow-up.

NCT ID: NCT02374775 Active, not recruiting - Clinical trials for Myocardial Infarction

Exploring the MEchanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and computationaL Fluid Dynamic

EMERALD
Start date: September 2014
Phase: N/A
Study type: Observational

The EMERALD trial is a multinational, multicenter study. The patients presented with AMI/definite evidence of plaque rupture and had underwent coronary CT angiography from 1 month to 2 year prior to the event will be retrospectively searched. Plaques in the non-culprit vessels will be regarded as internal control to the ruptured plaque in the culprit vessel.

NCT ID: NCT02352402 Active, not recruiting - Clinical trials for Coronary Artery Disease

The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery

POPular CABG
Start date: March 2015
Phase: Phase 3
Study type: Interventional

In the POPular CABG study we investigate if the addition of ticagrelor, a drug that inhibits blood platelets from clotting, to treatment with aspirin will reduce the rate of saphenous vein graft occlusion as assessed with coronary computed tomography angiography at 1 year after coronary artery bypass grafting surgery.

NCT ID: NCT02324660 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

SCAP
Start date: December 2014
Phase: N/A
Study type: Interventional

Several studies and registries suggested that the concomitant presence of acute coronary syndromes (ACS) and chronic obstructive pulmonary disease (COPD) is significantly associated with poor prognosis. It has been suggested that diagnosis of COPD is frequently missing. Thus, it is plausible that a significant percentage of patients with ACS may have unrecognized COPD. This missing diagnosis may contribute significantly to poor prognosis. The investigators suppose that the concomitant use of peak expiratory flow (PEF) measurement and of Respiratory Health Screening Questionnaire (RHSQ, adapted version) could be useful as screening test for COPD in patient smokers or former smokers admitted to hospital with a diagnosis of ACS. In all screened patients COPD diagnosis will be confirmed (or not) two months after hospital discharge with spirometry. In the same setting of patients, the investigators will characterize the underlying pathological mechanisms, evaluating several inflammation, platelet and endothelial markers.

NCT ID: NCT02299245 Active, not recruiting - Telomere Shortening Clinical Trials

Rosuvastatin Effect on Telomere-telomerase System in ACS

Start date: October 2014
Phase: Phase 4
Study type: Interventional

Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. Telomere length and telomerase activity, therefore, correlates with the risk of CHD and atherosclerosis. A present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. This suggests a positive relationship of telomere and telomerase system with the treatment with statins in CHD patients.

NCT ID: NCT02284191 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

RAPID-CTCA
Start date: March 2015
Phase: N/A
Study type: Interventional

This study aims to investigate the effect of early CTCA in patients with suspected or confirmed Acute Coronary Syndrome (ACS) presenting to the Emergency Department (ED) or Medical Assessment Unit (MAU), upon interventions, event rates and health care costs in a pragmatic clinical trial and economic evaluation up to 1 year after the trial intervention. The primary objective will be to investigate the effect of the intervention on all-cause death or subsequent type 1 or type 4b MI at one year, measured as time to first such event.

NCT ID: NCT02248311 Active, not recruiting - Clinical trials for Coronary Artery Disease

"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population

PRECISED
Start date: September 2014
Phase: N/A
Study type: Observational

Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke). In addition, Cardiovascular ischemic events in Type 2 Diabetes population have worse prognosis than in general population. In fact, there is sufficient experimental evidence indicating that diabetes exaggerates the deleterious effects of ischemic events and worsens their outcome. A prolonged sub-clinical phase exists before a Cardiovascular event occurs in Type 2 Diabetes patients. Therefore, new strategies aimed at identifying those patients with this subclinical Cardiovascular Diabetes and, consequently, more prone to develop Cardiovascular events is a challenge to be met.